Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients
| Autor: | Laura Bau, Sergio Martínez-Yélamos, Maria Alba Mañé-Martínez, L Romero-Pinel, María Martínez-Iniesta, Elisabet Matas |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Adult Male Myxovirus Resistance Proteins Treatment response medicine.medical_specialty Neurology Real-Time Polymerase Chain Reaction Gastroenterology 03 medical and health sciences 0302 clinical medicine Multiple Sclerosis Relapsing-Remitting Interferon Internal medicine medicine Humans Immunologic Factors Prospective Studies Prospective cohort study Proportional Hazards Models Interferon beta business.industry Proportional hazards model Multiple sclerosis Interferon-beta medicine.disease 030104 developmental biology Treatment Outcome Immunology Biomarker (medicine) Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of neurology. 263(4) |
| ISSN: | 1432-1459 |
| Popis: | The aim of this study is to investigate whether induction of myxovirus resistance protein A (MxA) mRNA after 3 months of interferon-β administration is related to the treatment response in multiple sclerosis (MS) patients. In this prospective study, MS patients were enrolled before starting treatment. Demographic, clinical and radiological variables were recorded. Blood samples were obtained before, and at 3 and 12 months after interferon-β treatment. Real-time PCR was used to analyze MxA mRNA expression. Patients were classified as MxA-low or -high depending on MxA levels at baseline, and as MxA-induced or -non-induced according to whether an increase in MxA expression was detected at month 3. Time to the next relapse was investigated using Cox proportional hazards regression analysis. One hundred and four patients were selected and followed for a median of 2.2 years (IQR 1.6-3.5). On Cox regression analysis, a higher EDSS score before treatment (HR 1.57; 95 % CI 1.02-2.40; p = 0.039), MxA-high status at baseline (HR 2.71; 95 % CI 1.26-5.81; p = 0.010), and MxA-non-induced at month 3 (HR 2.49; 95 % CI 1.08-5.68; p = 0.031), were predictors of poor response to interferon-β in naive MS patients. Patients showing a lower capacity for MxA induction following 3 months of interferon-β treatment are more likely to be non-responders to this therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink